Cellceutix Corp (OTC:CTIX) Free of Side Effects

Repost This

Las Vegas, NV -- (SBWIRE) -- 02/21/2013 -- Cellceutix Corp (OTC:CTIX) has been working with the Harvard Medical School recently to research over its eight major drugs. The major focus has been on the Kevetrin and Prurisol, the two main stream products of the company.

The good news for Cellceutix Corp is that no side effects are found in any of its products related to the cancer therapies. The research in progress is conducted in Israel at the Deaconess Medical Center.

The share price of Cellceutix Corp is currently trading at $1.69. Its price history of the last one year shows that, the stock price has touched the highest of $2.47 while its lowest stood at $0.45. The company has outstanding shares of 93.17 million.

To know what AwesomePennyStocker projects for Cellceutix Corp for both long term and short term, please click here: CTIX

AwesomePennyStocker is all about parabolic penny stocks that make epic moves up and reap massive gains for investors. Penny Stocks are heating up and APSR will reports on all of them letting investors know the difference between the winners and the losers. Come visit AwesomePennyStocker for yourself and see what everyone is talking about!

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at Release of Liability: Through use of this website viewing or using you agree to hold, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical., nor any of its affiliates are not registered investment advisors or broker dealers.